About Karen Jones

Dr Karen Jones graduated from the University of Liverpool with a degree in Pharmacology. After researching the basis for naphthoquinone and biguanide synergy, Karen also gained her PhD from the University of Liverpool. Karen worked at Astra Zeneca for some 14 years, most recently as project lead for multiple high throughput screening campaigns supporting projects in a range of disease areas including Neuroscience, Oncology, Cardiovascular and Metabolic disease. Previously to this Karen delivered high quality data from multiple in vitro assay formats, developed ion channel assays used to screen multiple ion channel targets, always improving procedures where possible and driving forward projects by focusing on quality and robustness.

N-Ethylmaleimide increases KCC2 cotransporter activity by modulating transporter phosphorylation.

Abstract K+/Cl- cotransporter 2 (KCC2) is selectively expressed in the adult nervous system and allows neurons to maintain low intracellular Cl- levels. Thus, KCC2 activity is an essential prerequisite for fast hyperpolarizing synaptic inhibition mediated by type A γ-aminobutyric acid (GABAA) receptors, which are Cl--permeable, ligand-gated ion channels. Consistent with this, deficits in the activity of KCC2 [...]

By |2018-07-05T13:46:47+00:00December 1st, 2017|Ion Channels, Publications|Comments Off on N-Ethylmaleimide increases KCC2 cotransporter activity by modulating transporter phosphorylation.

The small molecule CLP257 does not modify activity of the K+/Cl- co-transporter KCC2 but does potentiate GABA A receptor activity.

Read more here: RA Cardarelli, K Jones, LI Pisella, HJ Wobst, LJ McWilliams, PM Sharpe, MP Burnham, DJ Baker, I Chudotvorova, J Guyot, L Silayeva, DH Morrow, N Dekker, S Zicha, PA Davies, J Holenz, ME Duggan, J Dunlop, RJ Mather, Q Wang, I Medina, NJ Brandon, TZ Deeb and SJ Moss. The small molecule CLP257 [...]

By |2018-07-11T14:46:53+00:00December 1st, 2017|Ion Channels, Publications|Comments Off on The small molecule CLP257 does not modify activity of the K+/Cl- co-transporter KCC2 but does potentiate GABA A receptor activity.

A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERD’s).

Abstract Here, we describe an approach to identify novel selective estrogen receptor downregulator (SERD) compounds with improved properties such as oral bioavailability and the potential of increased efficacy compared to currently marketed drug treatments. Previously, methodologies such as Western blotting and transient cell reporter assays have been used to identify and characterize SERD compounds, but [...]

By |2018-07-05T13:35:31+00:00December 1st, 2015|Publications|Comments Off on A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERD’s).